Kalathure et al. evaluated the more than 800 genes associated with HD considering their strengths of association and biological functions and determined the most promising therapeutic targets besides HTT to be SUMO1, BZW1, SF3B1, CREB1, FZD5, DNAJB2, CDK5R2, ARPC2, S100P, WDR1, ADD1, WHSC2, HSPA4, SKP1, ETF1, HSPA9, UBE2D2, HDAC3, TCERG1, PPARGC1B, FRK, RPS12, MED23, MAP3K5, and GRM1 [27]. This evidence concerns the gene ADD1 and Huntington disease.